Background: The management of advanced epithelial ovarian cancer (EOC) has evolved to become a combination of initial cytoreductive surgery (CRS) followed by chemotherapy. Chemotherapy has been regarded as standard therapy for the majority of women with advanced EOC for several decades. A thorough understanding of drug resistance mechanisms is needed, as this remains the largest obstacle in treating patients with recurrent disease. The aim of characterized by age of women, type, stage, grade and clinical staging of the tumor.Methods: Data from regimens containing platinum (cisplatin or carboplatin) used in treating ovarian carcinoma in Sarjito General Hospital were analyzed prospectively. Relative dose intensity was calculated as a fraction of the dosage of a drug in the standard regimen of cyclophosphamide, doxorubicin, and platinum.Results:   The higher age of women will have lower response to chemotherapy. Women aged below 50 years old are much higher responsive to chemotherapy.Conclusion: Cisplatin based chemotherapy has a better response to ovarian carcinoma in earlier stage. In higher stage, it will give a complete removal of all macroscopic tumor tissue.

Background: According to data from the "Endometrial Cancer Report" by the World Cancer Research Fund and the American Institute for Cancer Research (WCRFI), endometrial cancer is the sixth most common malignancy in the world and is the largest cancer in female organs, after cervical cancer. This incidence is increasing every year, it is predicted to increase about 5% of new cases each year. The main prognostic factors of endometrial cancer are determined by the histological type, stage, degree, differentiation of the tumor, invasive myometrial level and increase in lympho-vascular invasion. In addition to determining the histopathological factors, the prognosis is also determined from the clinical patient. Several studies have shown certain clinical factors also improve the condition and prognosis of the disease. Prognosis of this disease with the quality of life of patients becomes an interesting topic to discuss. Besides that quality of life is also a measure of therapeutic success. The better the prognosis of a disease, the better the quality of life, the higher the success rate of therapy (Greimel, 2010).Objective: To know correlation between clinicohistopathological and quality of life in patients with endometrial cancer after undergoing surgery at Sardjito Hospital, Yogyakarta.Method: The research is analytic with cross sectional approach. Patients with endometrial cancer who have undergone total hysterectomy and bisalpingoophorectomy surgery are assessed for their quality of life through interviews and filling out questionnaires in the EORTC QLQ-C 30 and QLQ-EN 24 modules.Results and Discussion: This study, most people with endometrial cancer aged 55-65 years were 34 people (42%) and diagnosed after menopause with a range of age >55 years as many as 43 people (53.1%). This study cannot prove the hypothesis that age, parity, body mass index, type of histopathology and KGB involvement have a relationship with the quality of life of cancer patients (p >0.05). But in contrast to the stage of early cancer (OR 3.17, p=0.044 (CI 95% 1.03-9.75)) and good and moderate differentiation (OR 4.471, p=0.023 (CI 95% 1.23-16.24)) have a significant relationship with quality of life.Conclusion: Clinicohistopathological factors (cancer stage and tumor differentiation) have a correlation with the quality of life at patients with postoperative endometrial cancer in  Sardjito Hospital Keywords: Endometrial cancer; clinicohistopathological factors; quality of life

Background: The therapy for stage IIB cervical cancer according to FIGO is concurrent chemoradiation. The neoadjuvant chemotherapy followed by radical hysterectomy is an alternative therapy to improve the survival rate of cancer patients. Cervical cancer is mainly caused by the infection of Human Papilloma Virus (HPV), which contains protein E6 and E7 that downregulate the apoptotic function of p53. The absent of p53 wild-type and the present of p53 mutation play roles on the cervical cancer pathogenesis.Objective: To analyze the association between the expression of mutant p53 to the stage IIB cervical cancer operability after neoadjuvant chemotherapyMethod: This study was a prospective cohort, using 40 of 67 patient who met eligibility criteria. The parafin block from cervical tissue were processed for immunohistochemical staining of p53 using Anti-mutant p53 antibody [Y5] ab32049, Abcam, USA. Two study groups were assessed as: 1) weak and 2) strong expression of mutant p53 expression after neoadjuvant chemotherapy based on H-score. Both group (weak and strong) were comparable in term of mutant p53 expression. In this study, the evaluation of operability was performed clinically. Age, BMI, histopathology, grade of differentiation, and regiment were also evaluated as the external variables. Chi square test, and logistic regression analysis were used for statistical analysis.Results and Discussion: The rate of cervical cancer operability after chemotherapy was 19 out of 40 (47.5%). The strong expression of mutant p53 was observed in 6 subjects (15%). There was no significant association between weak vs strong expression of mutant p53 to the operability of the cancer (RR 1.5, CI 95% 0.46-4.88, p 0.45). Multivariate analysis showed that combination (50 mg/m2 dan 5 fluorourasil 450 mg/m2) was significantly correlated the operability (OR 7.02, CI 95% 1.27-40.07,  p 0.03).  Conclusion: The expression of mutant p53 not correlate with operability after neoadjuvant chemotherapy, but combination  regiment was.Keywords: expression of mutant p53, stage IIB of cervical cancer, neoadjuvant chemotherapy, operability

No abstract

Cervical cancer remains one of the malignancies with a high burden worldwide. There were 569,847 new cases and 311,365 deaths recorded globally in 2018. According to Globocan 2018, it is currently ranked fourth for women and tenth overall with an incidence rate of 13.1 per 100,000 population. Cervical cancer is also the ninth most common cause of death by cancer, with a mortality rate of 6.9 per